PL2627346T3 - Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu zapalenia błony naczyniowej oka - Google Patents

Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu zapalenia błony naczyniowej oka

Info

Publication number
PL2627346T3
PL2627346T3 PL11775734.4T PL11775734T PL2627346T3 PL 2627346 T3 PL2627346 T3 PL 2627346T3 PL 11775734 T PL11775734 T PL 11775734T PL 2627346 T3 PL2627346 T3 PL 2627346T3
Authority
PL
Poland
Prior art keywords
uveitis
cell
treatment
signal transduction
transduction pathway
Prior art date
Application number
PL11775734.4T
Other languages
English (en)
Inventor
Jean-Marc Combette
Catherine Deloche
Claire Abadie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/006284 external-priority patent/WO2012048721A1/en
Application filed filed Critical
Publication of PL2627346T3 publication Critical patent/PL2627346T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11775734.4T 2010-10-14 2011-10-14 Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu zapalenia błony naczyniowej oka PL2627346T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2010/006284 WO2012048721A1 (en) 2010-10-14 2010-10-14 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
EP2011000307 2011-01-25

Publications (1)

Publication Number Publication Date
PL2627346T3 true PL2627346T3 (pl) 2016-11-30

Family

ID=44862926

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11775734.4T PL2627346T3 (pl) 2010-10-14 2011-10-14 Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu zapalenia błony naczyniowej oka
PL14004427T PL2902035T3 (pl) 2010-10-14 2011-10-14 Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu chorób zapalnych oka

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14004427T PL2902035T3 (pl) 2010-10-14 2011-10-14 Przechodzące przez komórkę peptydowe inhibitory szlaku przekazywania sygnałów przez JNK do zastosowania w leczeniu chorób zapalnych oka

Country Status (7)

Country Link
EP (2) EP2627346B1 (pl)
CY (1) CY1120936T1 (pl)
DK (2) DK2902035T3 (pl)
ES (2) ES2575226T3 (pl)
HK (2) HK1187266A1 (pl)
PL (2) PL2627346T3 (pl)
WO (1) WO2012048893A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) * 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US10624948B2 (en) 2013-06-26 2020-04-21 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2015197098A1 (en) * 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
ES2949982T3 (es) * 2014-06-26 2023-10-04 Xigen Inflammation Ltd Inhibidores peptídicos permeables en células de la ruta de transducción de señales de JNK para el tratamiento de la cistitis
DE102016111708A1 (de) 2016-06-27 2017-12-28 Heiko Schmidt Gelenkanordnung, vorgefertigte Baugruppe sowie Verfahren zur Herstellung einer vorgefertigten Baugruppe einer Gelenkanordnung
CN108060223A (zh) * 2017-12-29 2018-05-22 北京泱深生物信息技术有限公司 Atf2基因的新应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0454781B1 (en) 1989-01-23 1998-12-16 Chiron Corporation Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5747641A (en) 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
AU689758B2 (en) 1992-10-09 1998-04-09 Advanced Tissue Sciences, Inc. Liver reserve cells
CN1208438A (zh) 1995-07-28 1999-02-17 玛丽·柯里癌症治疗中心 转运蛋白及其应用
MXPA05005161A (es) * 2002-11-18 2005-07-22 Celgene Corp Metodos de utilizacion y composiciones que comprenden (-)3- (3, 4-dimetoxi- fenil)-3 -(1-oxo -1, 3-dihidro- isoindol- 2-il)- propionamida.
WO2008006046A1 (en) * 2006-07-06 2008-01-10 Case Western Reserve University Ceramide composition and use thereof in treatment of ocular diseases
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
KR20120022721A (ko) * 2009-03-30 2012-03-12 산텐 세이야꾸 가부시키가이샤 ＪＮＫ(ｃ-Ｊｕｎ 아미노 말단 키나제) 저해 펩티드를 이용한 망막 질환의 예방 또는 치료제, 망막 질환의 예방 또는 치료 방법, 및 이 펩티드의 용도

Also Published As

Publication number Publication date
EP2627346B1 (en) 2016-03-23
DK2627346T3 (en) 2016-06-13
ES2688030T3 (es) 2018-10-30
EP2902035B1 (en) 2018-06-20
HK1210056A1 (en) 2016-04-15
EP2627346A1 (en) 2013-08-21
DK2902035T3 (en) 2018-09-24
WO2012048893A1 (en) 2012-04-19
PL2902035T3 (pl) 2019-04-30
HK1187266A1 (zh) 2014-04-04
CY1120936T1 (el) 2019-12-11
ES2575226T3 (es) 2016-06-27
EP2902035A1 (en) 2015-08-05

Similar Documents

Publication Publication Date Title
HK1187266A1 (zh) 信號轉導途徑的細胞透性肽抑制劑用於治療葡萄膜炎
HK1221413A1 (zh) 信號轉導途徑的細胞穿膜肽抑制劑用於治療各種疾病的應用
HK1257444A1 (zh) Cdc7激酶抑制劑以及其用途
IL232699A0 (en) Use of cell-permeable peptide inhibitors of signal transmitters in the jnk pathway to treat dry eye syndrome
HK1202333A1 (en) Combination of kinase inhibitors and uses thereof
IL222361A0 (en) Lysine specific demethylase-1 inhibitors and their use
HK1224225A1 (zh) 信號轉導途徑的細胞滲透肽抑制劑用於治療多種疾病的新用途
HK1179623A1 (en) Inhibitors of protein kinases
ZA201206456B (en) Uses of dgati inhibitors
EP2242501A4 (en) THERAPEUTIC INHIBITORS OF PAI-I FUNCTION AND METHODS OF USE
ZA201300012B (en) Synthesis and use of kinase inhibitors
ZA201300009B (en) Oral formulation of kinase inhibitors
GB0803895D0 (en) Inhibitors of glyoxalase
LU91725B1 (en) Novel uses of V-ATPASE inhibitors
GB0801939D0 (en) Peptide inhibitors of lentiviral replication
GB0908609D0 (en) New use of isoQC inhibitors
GB201017098D0 (en) Carbonic anhydrase inhibitors
GB201002412D0 (en) Carbonic anhydrase inhibitors
GB201003949D0 (en) Inhibitors of protein kinases
GB201019938D0 (en) Determination of therapeutic agents
GB0903651D0 (en) Inhibitors of glyoxalase